FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Quality of Life With Busulfan and Fludarabine Compared With Busulfan and Cyclophosphamide
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
Response-Adapted Intensification in Multiple Myeloma After Suboptimal Response to Induction
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Nurse Practitioner-Led Rapid Diagnosis Clinic May Reduce Time to Diagnosis in Lymphoma
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Gastrointestinal Involvement May Be a Sign of Waldenström Macroglobulinemia
Gastrointestinal-tract involvement may be a comorbid condition in patients with Waldenström macroglobulinemia.
Survival Outcomes Associated With Infusion Reactions With Rituximab in Diffuse Large B-Cell Lymphoma
A retrospective cohort analysis found that patients with DLBCL who experienced infusion reactions during treatment with rituximab had prolonged overall survival. In addition, progression-free survival was affected in subsets of patients with DLBCL.
No Influence of Measurable Residual Disease on Haploidentical Transplantation Outcomes in AML
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera
Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.
Novel Therapies on the Horizon for Waldenström Macroglobulinemia
New treatments are in clinical development for Waldenström macroglobulinemia, a disease for which there is unmet clinical need.
Biosimilar Truxima Now Available for Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Truxima (rituximab-abbs; Teva and Celltrion), a biosimilar to Rituxan (rituximab; Genentech) will be available in the US the week of November 11, 2019 for the treatment of adults with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Hematologic Scoring System Predicts Survival in Multiple Myeloma
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Exercise Intolerance, Neurocognitive Dysfunction in Survivors of Childhood Acute Lymphoblastic Leukemia
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Reduced Rates of Central Nervous System Relapse in Patients With High-Risk Pediatric ALL
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Single-Cell RNA Sequencing Characterizes T-Cell Impairment in CAR-T Cells Derived From Patients With CLL
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Off-the-Shelf CAR T Cells From Umbilical Cord Blood Show Unique Features
Anti-CD19 chimeric antigen receptor T cells made from umbilical cord blood cells had a distinct phenotype and may offer off-the-shelf potential.
19-28z CAR-T Therapy in Children and Young Adults With Relapsed/Refractory ALL: Promising Early Results
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
Measurable Residual Disease Status: A Strong Prognostic Indicator in B-Cell Acute Lymphoblastic Leukemia
Researchers conducted a meta-analysis of 23 studies to determine the influence of measurable residual disease on survival outcomes.
Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea
This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
